The condition does not retire at menopause

What the evidence says

The condition does not end at perimenopause; it changes shape. Cycles often become more regular in the years before menopause as the follicle pool declines, which can feel like the condition lifting, but the androgen and metabolic sides persist. In a Swedish cohort of women with the condition over 45 (median age 50), more than 40% still had hirsutism.

In a Dutch study of 205 women with the condition, cycles shortened steadily with age. A 2023 review of studies after menopause found androgen levels stayed higher than in other women, and diabetes and high blood pressure were more common, largely tied to excess weight that often comes with the condition. This is why screening does not retire, and the 2023 international guideline treats the condition as lifelong. Perimenopause with the condition can also be harder to read, because irregular cycles were already the baseline. General menopause guidance diagnoses perimenopause after 45 from hot flushes and night sweats together with changing periods, not from blood tests, so new symptoms matter more than the calendar alone.

What this does not show

'Changes shape' is the population arc, not a forecast of your forties, your menopause timing, or which features will persist for you. The over-40% figure comes from one Swedish cohort, and hirsutism numbers are always shaped by how they are scored and by hair removal before anyone counts. The review of studies after menopause rated its evidence as low quality. Telling perimenopause apart from an irregular baseline is genuinely clinical work, and nothing here can say which you are in.

Sources, as Neta holds them

1. Elting MW, Korsen TJM, Rekers-Mombarg LTM, Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod. 2000;15(1):24-8. doi:10.1093/humrep/15.1.24

   People compared with each other · 205 participants

2. Persson S, Ubhayasekera KA, Bergquist J, Turkmen S, Sundström Poromaa I, Elenis E. Hyperandrogenic symptoms are a persistent suffering in midlife women with PCOS; a prospective cohort study in Sweden. Biomedicines. 2023;11(1):96. doi:10.3390/biomedicines11010096

   People compared with each other · 198 participants

3. Millán-de-Meer M, Luque-Ramírez M, Nattero-Chávez L, Escobar-Morreale HF. PCOS during the menopausal transition and after menopause: a systematic review and meta-analysis. Hum Reprod Update. 2023;29(6):741-72. doi:10.1093/humupd/dmad015

   Systematic review

4. Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-69. doi:10.1210/clinem/dgad463

   Guideline synthesis

5. National Institute for Health and Care Excellence. Menopause. NICE guideline NG23. London: NICE. Available from: https://www.nice.org.uk/guidance/ng23/chapter/recommendations

   Guideline synthesis